《新股消息》凱萊英(06821.HK)以近中間價每股388元定價
內地外包藥物開發及生產解決方案供應商凱萊英(06821.HK)公佈,釐定每股發售價爲388元,爲招股價350至410元的中間價定價,該股將於週五(10日)掛牌。聯席保薦人爲高盛及中信證券。
公司計劃發行1,841.54萬股,當中10%在港公開發售,90%爲國際發售,是次上市所得款項淨額約爲67.08億元,約20%擬用於進一步提高小分子CDMO解決方案的產能及能力;約35%用於加強新興服務並擴大服務內容;約20%用於投資研發項目及保持公司技術領先地位(尤其是在連續生產技術及生物合成技術領域的領先地位);約15%用於選擇性地進行戰略投資及收購;約10%用作營運資金及一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.